Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease

Martin A. Josephson, Sanjiv Kaul, James Hopkins, Donald Kvam, Bramah N. Singh

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Flecainide, a new antiarrhythmic agent with poorly defined hemodynamic actions, was studied in 22 patients with coronary artery disease. Intravenous infusions of 1 mg/kg and 2 mg/kg resulted in respective increases in right atrial pressure (12%, p <0.05; 15%, p <0.01), mean pulmonary artery pressure (27%, p <0.01; 28%, p <0.01), and pulmonary capillary wedge pressure (44%, p <0.05; 33%, p <0.01). Cardiac index decreased 8% (p <0.05) after 1 mg/kg flecainide and 12% (p <0.05) after the 2 mg/kg dose. The mean left ventricular ejection fraction decreased by 15% (p <0.01) and 16% (p <0.01), respectively, 10 minutes after 1 mg/kg and 2 mg/kg of flecainide. Minimal increases in the heart rate (<5%) and no significant change in arterial pressure occurred 5 to 10 minutes after flecainide and were associated with borderline and variable increases in pulmonary and systemic vascular resistances. Flecainide diluent did not induce changes in pulmonary capillary wedge pressure or left ventricular ejection fraction. Thus, flecainide exerts a moderate but significant negative inotropic effect which may be clinically significant in patients with severely compromised ventricular function.

Original languageEnglish (US)
Pages (from-to)41-45
Number of pages5
JournalAmerican Heart Journal
Volume109
Issue number1
DOIs
StatePublished - 1985
Externally publishedYes

Fingerprint

Flecainide
Ventricular Function
Coronary Artery Disease
Hemodynamics
Pulmonary Wedge Pressure
Vascular Resistance
Stroke Volume
Atrial Pressure
Intravenous Infusions
Pulmonary Artery
Arterial Pressure
Heart Rate
Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. / Josephson, Martin A.; Kaul, Sanjiv; Hopkins, James; Kvam, Donald; Singh, Bramah N.

In: American Heart Journal, Vol. 109, No. 1, 1985, p. 41-45.

Research output: Contribution to journalArticle

Josephson, Martin A. ; Kaul, Sanjiv ; Hopkins, James ; Kvam, Donald ; Singh, Bramah N. / Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. In: American Heart Journal. 1985 ; Vol. 109, No. 1. pp. 41-45.
@article{ecb24d90c0be4ee8af02c75fbee4cbcc,
title = "Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease",
abstract = "Flecainide, a new antiarrhythmic agent with poorly defined hemodynamic actions, was studied in 22 patients with coronary artery disease. Intravenous infusions of 1 mg/kg and 2 mg/kg resulted in respective increases in right atrial pressure (12{\%}, p <0.05; 15{\%}, p <0.01), mean pulmonary artery pressure (27{\%}, p <0.01; 28{\%}, p <0.01), and pulmonary capillary wedge pressure (44{\%}, p <0.05; 33{\%}, p <0.01). Cardiac index decreased 8{\%} (p <0.05) after 1 mg/kg flecainide and 12{\%} (p <0.05) after the 2 mg/kg dose. The mean left ventricular ejection fraction decreased by 15{\%} (p <0.01) and 16{\%} (p <0.01), respectively, 10 minutes after 1 mg/kg and 2 mg/kg of flecainide. Minimal increases in the heart rate (<5{\%}) and no significant change in arterial pressure occurred 5 to 10 minutes after flecainide and were associated with borderline and variable increases in pulmonary and systemic vascular resistances. Flecainide diluent did not induce changes in pulmonary capillary wedge pressure or left ventricular ejection fraction. Thus, flecainide exerts a moderate but significant negative inotropic effect which may be clinically significant in patients with severely compromised ventricular function.",
author = "Josephson, {Martin A.} and Sanjiv Kaul and James Hopkins and Donald Kvam and Singh, {Bramah N.}",
year = "1985",
doi = "10.1016/0002-8703(85)90413-2",
language = "English (US)",
volume = "109",
pages = "41--45",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease

AU - Josephson, Martin A.

AU - Kaul, Sanjiv

AU - Hopkins, James

AU - Kvam, Donald

AU - Singh, Bramah N.

PY - 1985

Y1 - 1985

N2 - Flecainide, a new antiarrhythmic agent with poorly defined hemodynamic actions, was studied in 22 patients with coronary artery disease. Intravenous infusions of 1 mg/kg and 2 mg/kg resulted in respective increases in right atrial pressure (12%, p <0.05; 15%, p <0.01), mean pulmonary artery pressure (27%, p <0.01; 28%, p <0.01), and pulmonary capillary wedge pressure (44%, p <0.05; 33%, p <0.01). Cardiac index decreased 8% (p <0.05) after 1 mg/kg flecainide and 12% (p <0.05) after the 2 mg/kg dose. The mean left ventricular ejection fraction decreased by 15% (p <0.01) and 16% (p <0.01), respectively, 10 minutes after 1 mg/kg and 2 mg/kg of flecainide. Minimal increases in the heart rate (<5%) and no significant change in arterial pressure occurred 5 to 10 minutes after flecainide and were associated with borderline and variable increases in pulmonary and systemic vascular resistances. Flecainide diluent did not induce changes in pulmonary capillary wedge pressure or left ventricular ejection fraction. Thus, flecainide exerts a moderate but significant negative inotropic effect which may be clinically significant in patients with severely compromised ventricular function.

AB - Flecainide, a new antiarrhythmic agent with poorly defined hemodynamic actions, was studied in 22 patients with coronary artery disease. Intravenous infusions of 1 mg/kg and 2 mg/kg resulted in respective increases in right atrial pressure (12%, p <0.05; 15%, p <0.01), mean pulmonary artery pressure (27%, p <0.01; 28%, p <0.01), and pulmonary capillary wedge pressure (44%, p <0.05; 33%, p <0.01). Cardiac index decreased 8% (p <0.05) after 1 mg/kg flecainide and 12% (p <0.05) after the 2 mg/kg dose. The mean left ventricular ejection fraction decreased by 15% (p <0.01) and 16% (p <0.01), respectively, 10 minutes after 1 mg/kg and 2 mg/kg of flecainide. Minimal increases in the heart rate (<5%) and no significant change in arterial pressure occurred 5 to 10 minutes after flecainide and were associated with borderline and variable increases in pulmonary and systemic vascular resistances. Flecainide diluent did not induce changes in pulmonary capillary wedge pressure or left ventricular ejection fraction. Thus, flecainide exerts a moderate but significant negative inotropic effect which may be clinically significant in patients with severely compromised ventricular function.

UR - http://www.scopus.com/inward/record.url?scp=0022205121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022205121&partnerID=8YFLogxK

U2 - 10.1016/0002-8703(85)90413-2

DO - 10.1016/0002-8703(85)90413-2

M3 - Article

VL - 109

SP - 41

EP - 45

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -